Thirteen mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa (ADRP) have been produced by transfection of cloned cDNA into tissue culture cells. Three mutants [class I: Phe45 --Leu, termination (deletion of C-terminal positions 344-348), and Pro-347 --Leul resemble wild-type rhodopsin in yield, regenerability with 11-cis-retinal, and plasma membrane localization. Ten mutants Met, His, Thr-58 --Arg, Val-87 -* Asp, Gly-89 Asp, Gly-106 -Trp, Arg-135 --Leu, Arg-135 Trp, Tyr-178 -+ Cys, and Gly] accumulate to significantly lower levels, regenerate with 11-cis-retinal variably or not at all, and are transported inefficiently to the plasma membrane, remaining primarily in the endoplasmic reticulum. These data suggest that there are at least two distinct biochemical defects associated with different rhodopsin mutants in ADRP.
Retinitis pigmentosa (RP) is a group of inherited disorders that cause a progressive loss of retinal function. The hallmarks ofRP are decreased rod sensitivity, progressive loss of visual fields, a diminished electroretinographic response referable to photoreceptors, and characteristic pigmentary deposits in the retina (1) .
Recently, some patients with autosomal dominant RP (ADRP) were found to carry mutations in the gene encoding rhodopsin, the visual pigment mediating rod vision (2) (3) (4) (5) . The mutations cosegregate with RP and are absent from control populations with normal vision. In a previous study of 161 unrelated families with ADRP, 39 were found to carry 1 of 13 different point mutations in the rhodopsin coding region (5) . The goal of the present study is to define the biochemical differences between wild-type (wt) rhodopsin and the variants responsible for ADRP. For this purpose we have produced in tissue culture cells each of the 13 mutant human rhodopsins described above and determined their yield, regenerability with 11-cis-retinal, and subcellular localization.
MATERIALS AND METHODS
Tissue Culture Expression. A rhodopsin cDNA clone was isolated from a human retina cDNA library (6, 7) , and a fragment containing the entire coding region was inserted into the expression plasmid pCIS (8) . In vitro mutagenesis and production of opsin after transient or stable transfection of 293S cells were performed as described (9, 10) .
Absorbance Spectra. Cells from 20 10-cm plates were collected 60 hr after transient transfection, and membranes were prepared as described (9) except that the final membrane pellet was solubilized in 0.3 ml of 0.1 M sodium phosphate, pH 6.5/1 mM EDTA/1% 3-[(3-cholamidopropyl)-dimethylammoniol-1-propanesulfonate (CHAPS; Sigma). The solubilized sample was regenerated with li-cis-retinal, incubated with 50 mM hydroxylamine for 30 min, and the photobleaching difference spectrum was determined (9) .
Immunoblotting. Membrane samples prepared from cells 60 hr after transfection were mixed with an equal volume of 2x Laemmli sample buffer (lx = 0.125 M TrisHCl, pH 6.8/4% SDS/20o glycerol/10%o 2-mercaptoethanol/0.012% bromophenol blue), resolved on a SDS/12.5% polyacrylamide gel, and electroblotted onto nitrocellulose (11) . Immunoreactive protein was visualized by using a 1:1 mixture of monoclonal antibodies (mAbs) B6-30 and 1D4, which recognize, respectively, the amino-and carboxyl-terminal regions of rhodopsin (12, 13) , and the enhanced chemiluminescence detection system (Amersham).
Immunohistochemistry. For light microscopy, 293S cells were grown on glass cover slips coated with 0.1% gelatin, transfected as described above, and processed 24 hr after transfection. For fluorescent staining, cells were fixed for 10 min at room temperature in 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized for 3 min with ice-cold methanol, and incubated with mAb B6-30 or 1D4 (ascites diluted 1:5000), followed by fluorescein isothiocyanate-conjugated goat anti-mouse Ig. For avidin-biotin complex (ABC)-peroxidase staining, cells were rinsed with PBS, air-dried, fixed and permeabilized for 10 min with ice-cold methanol, and incubated with mAb B6-30 or 1D4 followed by biotinylated goat anti-mouse immunoglobulin.
For immuno-EM, cell lines were grown for 3-4 days on Aclar film prior to embedding in Lowicryl K4M as described (14, 15) . Thin sections were labeled with 0.1 mg of mAb 1D4 per ml for detection of wt rhodopsin and the P23H § mutant or with 0.025 mg ofa polyclonal sheep anti-opsin antibody per ml, which primarily detects the amino termini of vertebrate rhodopsins (16) for detection of wt rhodopsin and mutants P347L and Q344ter (Gln-344 --termination-i.e., deletion of C-terminal positions 344-348). Bound antibodies were detected with rabbit anti-mouse or rabbit anti-sheep IgG followed by goat anti-rabbit IgG bound to 10-nm gold particles as described (17 
RESULTS
Production ofRhodopsin Mutants in Tissue Culture. Each of 13 mutant rhodopsin sequences previously described in patients with ADRP was introduced into a cloned human rhodopsin cDNA by site-directed mutagenesis ( Fig. 1 
; ref. 5).
In an initial set of experiments, wt and mutant rhodopsin sequences were transiently transfected into a human embryonic kidney cell line (293S), and the expressed proteins were analyzed by immunoblotting (Fig. 2) . wt human opsin (the apoprotein of rhodopsin) expressed in 293S cells appears as a heterogeneous family of bands: the broad bands at 30-45 kDa and 60-75 kDa represent monomers and dimers, respectively, each of which is heterogeneously glycosylated as determined by endo F treatment (see below). Bovine opsin isolated from rod outer segments is known to aggregate upon denaturation; most likely the aggregation ofexpressed human opsin represents the same phenomenon.
The immunoblot patterns of the 13 human rhodopsin mutants fall into two groups. Mutants F45L, Q344ter, and P347L show electrophoretic patterns resembling that of wt and they accumulate to the wt level. The remaining 10 mutants appear predominantly as dimers or higher order multimers and accumulate to levels significantly lower than the wt. To determine whether or not the expressed proteins were correctly folded, we examined their ability to bind the chromophore 11-cis-retinal. Cell membranes from transiently transfected cells were solubilized in CHAPS and incubated with an excess of 11-cis-retinal for 2 hr in the dark. Absorbance spectra were recorded prior to and after photobleaching, and the difference spectra were calculated. In the difference spectra shown in Fig. 3 , the positive peak in the visible region corresponds to rhodopsin and the negative peak in the UV region corresponds to released all-transretinal. wt human rhodopsin produced in tissue culture cells and rhodopsin isolated from human retinas (18) have absorbance spectra that are indistinguishable.
Mutants F45L, Q344ter, and P347L produce photolabile pigments with absorbance spectra that are indistinguishable from wt. Mutants V87D and G89D produce photolabile pigments at greatly reduced yield compared with wt, a characteristic observed for each in three independent experiments. The remaining eight rhodopsin mutants consistently fail to produce detectable photopigments upon incubation with 11-cis-retinal. Subcellular Distribution of Rhodopsin Mutants. Immunocytochemistry. In the retina, opsin is synthesized on the rough endoplasmic reticulum (ER) and is transported via the Golgi apparatus to the plasma membrane (PM) (16, 19) . To examine the possibility that some of the rhodopsin mutants may be defective in intracellular transport, we examined their subcellular distribution in 293S cells.
wt opsin expressed in 293S cells accumulates primarily in the plasma membrane (Fig. 4 A and G and Fig. SA) . After transient transfection, the subcellular distribution of each rhodopsin mutant was determined by both immunofluorescent and immunoperoxidase staining of fixed and permeabilized cells with mAbs 1D4 and B6-30. (Fig. 4 C, E, and H) . The presence or absence of cell surface staining was confirmed for each mutant by staining nonpermeabilized cells with mAb B6-30, which recognizes rhodopsin's extracellular aminoterminal domain (data not shown). Post-embedding colloidal-gold immuno-EM revealed prominent PM labeling of cell lines expressing Q344ter and P347L ( Fig. 5 C and D) . Two cell lines expressing P23H showed no labeling with mAb 1D4 or sheep anti-opsin above the background level obtained by staining with normal mouse IgG or preimmune sheep IgG, respectively (Fig. 5B) Glycosylation Patterns. Bovine rhodopsin is N-glycosylated at Asn-2 and -15 (20) , sites that are conserved in the human rhodopsin sequence (7) . High-mannose core oligosaccharides are added to the N-glycosylation sites in the ER and are trimmed and elaborated in the Golgi apparatus (21) . Therefore, we examined the time course of acquisition and modification of N-linked oligosaccharides as a means of following the transit of newly synthesized opsin through the ER-Golgi-PM pathway.
293S cell lines expressing either wt opsin or the P23H mutant were labeled for 30 min with [35S]methionine, followed by a variable chase period ranging from 15 min to 6 hr. Radiolabeled opsin was purified by immunoprecipitation and analyzed by SDS/PAGE (Fig. 6A) . Newly synthesized wt opsin migrated predominantly as a 39-kDa band. During the chase period, this band decreased in intensity, and there was a concomitant increase in the intensity of a heterogeneous family of bands between 43 and 68 kDa that correspond to highly glycosylated monomeric opsin. (Opsin acquired oligosaccharides of larger average mass in stable cell lines than it did after transient transfection; compare Figs. 2 and 6.) No significant degradation was seen over the 6-hr chase period. By contrast, newly synthesized P23H mutant appeared as a triplet of bands at 31, 35, and 39 kDa. Over the 6-hr chase period, these bands appeared to be degraded; no higher molecular mass species were observed. Proc. Natl. Acad. Sci. USA 88 (1991) To identify the oligosaccharide structures associated with the different molecular mass opsin species, each was cleaved with either endo F (Fig. 6B) or endo H (Fig. 6C) . endo F cleaves from the protein all N-linked oligosaccharides; endo H cleaves the high-mannose form but not the complex Golgi forms. As expected, all ofthe higher molecular mass forms of opsin, both wt and mutant P23H, were cleaved by endo F to yield a species migrating at the position of the core polypeptide. In the wt sample, multimers were also present, presumably formed by aggregation ofdenatured opsin. The core polypeptide comigrated with the 31-kDa band, a mobility closely matching that reported for opsin synthesized in vitro (22) . Treatment with endo H cleaves only the 35-and 39-kDa species, producing the expected 31-kDa core polypeptide. These data show that the 35-and 39-kDa species carry high-mannose core oligosaccharides, whereas the oligosaccharides carried by the heterogeneous family of bands between 43 and 68 kDa have been modified by passage through the Golgi apparatus. The 31-, 35-, and 39-kDa species appear to represent polypeptides carrying 0, 1, and 2 high-nmannose oligosaccharides, respectively. Support for this assignment comes from the observation that mutant T17M, in which the Asn-Ala-Thr N-glycosylation site at positions 15-17 has been destroyed, produces only the 31-kDa and 35-kDa species. This biosynthetic analysis shows that wt opsin proceeds from ER to Golgi to PM with little turnover, whereas P23H does not proceed to the Golgi apparatus and is rapidly degraded.
After Table 1 summarizes the properties of wt and mutant rhodopsins described in this paper. Two major classes are evident: class I mutants resemble wt in yield, electrophoretic pattern, regenerability with 11-cis-retinal, and subcellular localization; class II mutants accumulate to significantly lower levels, appear predominantly as aggregates on immunoblots, regenerate with 11-cis-retinal to variable extents or not at all, and are transported inefficiently to the PM. A finer distinction can be made within class II between those mutants that show predominantly intracellular localization (class Ila) and those that also show significant cell surface localization (class Ilb). One member of class Ila, P23H, is the single most common rhodopsin mutation among patients with ADRP, accounting for 12-15% of cases in the United States (2, 5) .
The initial assignment of a causal role for these rhodopsin mutants in ADRP rested on their coinheritance with RP in affected families, and their absence in a control population with normal vision. The biochemical defects in class II mutants provide independent evidence for this assignment.
Implications for the Pathogenesis of RP. The behavior of class II mutants closely resembles that of a large number of constructed mutants in the extracellular domains of bovine rhodopsin (23) . Several class II mutations (G106W, Y178C, and D190G) reside near Cys-110 or Cys-187, two conserved residues that form an essential disulfide bond in bovine rhodopsin (24) . These mutations may destabilize the protein by interfering with disulfide bond formation. Class II rhodopsin mutants join a growing list of PM protein mutants that share the property of retention in the ER, including class 2 low density lipoprotein receptor mutants (25) and the most common allele of the cystic fibrosis transmembrane conductance regulator (26) . These data point to the existence of a mechanism in the ER that retains and degrades proteins that are incorrectly or incompletely folded or assembled (27) . It seems reasonable to suppose that synthesis of misfolded or unstable opsin may be deleterious to the photoreceptor.
The pathogenic mechanisms associated with class I mutants are not evident from the present set of experiments. It is possible that one of the class I mutants, F45L, represents a mild class II phenotype, as it is the most conservative ofthe amino acid substitutions studied. The other two class I mutants reside close to rhodopsin's carboxyl terminus and, together with a P347S mutation reported in another ADRP family (3) , imply an important functional role for this region.
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